A Phase 3 interventional study of Pregabalin and Placebo in Fibromyalgia and Sleep Disorders, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 50 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 3, Interventional, and Treatment
The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)
1,336 studies on the registry are indexed under Fibromyalgia; 266 are open to participants now.
This study's enrollment of 119 is above the median of 60 across 1,035 interventional studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 431 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
flexible dosing Lyrica 300-450mg/day
Drug: Pregabalin
Placebo
Drug: Placebo
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
Wake After Sleep Onset (WASO) at Weeks 5 and 11
WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography \[PSG\]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording \[i.e. awake epoch immediately prior to the end of the recording\]) on 2 consecutive nights divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)
Wake Time During Sleep (WTDS)
WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Wake Time After Sleep (WTAS)
WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Total Sleep Time (TST)
TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Sleep Efficiency (SE)
SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 1)
NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 2)
NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Latency to Persistent Sleep (LPS)
LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Hour of the Night
WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total).
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Each Quarter of the Night
WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments).
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Slow Wave Sleep (SWS)
SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Disturbance at Weeks 5 and 11
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline.
Time frame: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Problems Index II Weeks 5 and 11
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline.
Time frame: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Sleep Quality
Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores.
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Latency of Sleep Onset (LSO)
LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ.
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Daily Pain Score
Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores.
Time frame: Daily up to Day 73 or ET
Subjective Wake After Sleep Onset (sWASO)
sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values.
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Subjective Total Sleep Time (sTST)
sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values.
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
| Milestone | Placebo, Then Pregabalin | Pregabalin, Then Placebo |
|---|---|---|
| Started | 60 | 59 |
| Completed | 53 | 51 |
| Not completed | 7 | 8 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: No longer willing to participate | 2 | 0 |
| Withdrew: Protocol violation | 3 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | Placebo, Then Pregabalin | Pregabalin, Then Placebo |
|---|---|---|
| Started | 54 | 51 |
| Completed | 54 | 51 |
| Not completed | 0 | 0 |
| Milestone | Placebo, Then Pregabalin | Pregabalin, Then Placebo |
|---|---|---|
| Started | 53 | 51 |
| Completed | 52 | 50 |
| Not completed | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: No longer willing to participate | 0 | 1 |
WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography \[PSG\]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording \[i.e. awake epoch immediately prior to the end of the recording\]) on 2 consecutive nights divided by 2 at the end of each intervention period.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Wake After Sleep Onset (WASO) at Weeks 5 and 11 | 70.69 ± 3.78 | 51.54 ± 3.78 |
WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Wake Time During Sleep (WTDS) | 63.38 ± 2.90 | 45.83 ± 2.93 |
WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Wake Time After Sleep (WTAS) | 9.19 ± 1.55 | 7.38 ± 1.57 |
TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Total Sleep Time (TST) | 370.6 ± 4.65 | 396.2 ± 4.69 |
SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
| Percentage of time asleep | Placebo | Pregabalin |
|---|---|---|
| Sleep Efficiency (SE) | 77.21 ± 0.97 | 82.64 ± 0.98 |
NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period.
| Awakenings | Placebo | Pregabalin |
|---|---|---|
| Number of Awakenings After Sleep Onset (NAASO 1) | 26.92 ± 1.00 | 24.51 ± 1.00 |
NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
| Awakenings | Placebo | Pregabalin |
|---|---|---|
| Number of Awakenings After Sleep Onset (NAASO 2) | 10.16 ± 0.44 | 8.63 ± 0.45 |
LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Latency to Persistent Sleep (LPS) | 41.63 ± 3.70 | 34.45 ± 3.74 |
WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total).
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Hour 1 | 1.96 ± 0.27 | 1.62 ± 0.28 |
| Hour 2 | 5.66 ± 0.52 | 4.56 ± 0.53 |
| Hour 3 | 7.09 ± 0.54 | 4.65 ± 0.55 |
| Hour 4 | 8.95 ± 0.75 | 5.43 ± 0.75 |
| Hour 5 | 10.55 ± 0.90 | 7.54 ± 0.90 |
| Hour 6 | 11.26 ± 0.94 | 7.38 ± 0.95 |
| Hour 7 | 10.96 ± 0.91 | 8.38 ± 0.92 |
| Hour 8 | 17.08 ± 1.34 | 14.23 ± 1.35 |
WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments).
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Quarter 1 | 7.23 ± 0.63 | 5.98 ± 0.64 |
| Quarter 2 | 16.04 ± 1.05 | 10.04 ± 1.06 |
| Quarter 3 | 21.73 ± 1.58 | 14.90 ± 1.60 |
| Quarter 4 | 28.04 ± 1.98 | 22.60 ± 2.00 |
SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
| Percentage of total sleep time | Placebo | Pregabalin |
|---|---|---|
| Slow Wave Sleep (SWS) | 15.04 ± 1.01 | 17.18 ± 1.01 |
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline.
| Units on a scale | Placebo | Pregabalin |
|---|---|---|
| Change Week 1 to Week 5 (n=59, 56) | -19.0 ± 2.98 | -27.1 ± 3.06 |
| Change Week 7 to Week 11 (n=50, 52) | -2.23 ± 3.10 | -21.0 ± 3.04 |
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline.
| Units on a scale | Placebo | Pregabalin |
|---|---|---|
| Change Week 1 to Week 5 (n=59, 56) | -16.4 ± 2.37 | -21.9 ± 2.43 |
| Change Week 7 to Week 11 (50, 52) | -0.98 ± 2.51 | -14.4 ± 2.46 |
Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores.
| Unit on a scale | Placebo | Pregabalin |
|---|---|---|
| Week 1 | 4.79 ± 0.16 | 5.70 ± 0.17 |
| Week 2 | 4.95 ± 0.18 | 6.09 ± 0.18 |
| Week 3 | 5.09 ± 0.17 | 5.96 ± 0.17 |
| Week 4 | 5.17 ± 0.17 | 6.06 ± 0.17 |
LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Week 1 | 51.23 ± 2.61 | 43.56 ± 2.61 |
| Week 2 | 49.94 ± 2.92 | 42.27 ± 2.92 |
| Week 3 | 48.92 ± 4.01 | 43.24 ± 4.02 |
| Week 4 | 46.70 ± 2.68 | 40.51 ± 2.68 |
Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores.
| Units on a scale | Placebo | Pregabalin |
|---|---|---|
| Week 1 | 6.12 ± 0.18 | 5.42 ± 0.18 |
| Week 2 | 5.81 ± 0.18 | 5.10 ± 0.18 |
| Week 3 | 5.73 ± 0.19 | 5.14 ± 0.19 |
| Week 4 | 5.44 ± 0.20 | 4.92 ± 0.20 |
sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Week 1 | 80.86 ± 3.71 | 62.59 ± 3.73 |
| Week 2 | 75.48 ± 3.91 | 59.43 ± 3.92 |
| Week 3 | 74.97 ± 4.75 | 61.73 ± 4.76 |
| Week 4 | 69.65 ± 4.20 | 59.40 ± 4.21 |
sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values.
| Minutes | Placebo | Pregabalin |
|---|---|---|
| Week 1 | 336.8 ± 5.40 | 361.7 ± 5.41 |
| Week 2 | 341.9 ± 5.76 | 371.3 ± 5.77 |
| Week 3 | 344.1 ± 5.73 | 370.9 ± 5.74 |
| Week 4 | 352.5 ± 5.60 | 377.9 ± 5.61 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/111 (0%) | 21/111 (18.9%) |
| Pregabalin | — | 0/112 (0%) | 51/112 (45.5%) |
| Event | Placebo | Pregabalin |
|---|---|---|
| dizzinessNervous system disorders | 11/111 | 34/112 |
| somnolenceNervous system disorders | 5/111 | 23/112 |
| headacheNervous system disorders | 9/111 | 10/112 |
| nauseaGastrointestinal disorders | 3/111 | 8/112 |
| Age, Continuous(Years) | Entire Study Population |
|---|---|
| Mean | 48.4 ± 9.9 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 103 |
| Male | 16 |
| Medical Outcome Study Sleep Scale (MOS-SS) Sleep Disturbance Baseline Measure (Weeks 1 and 7)(Scores on a Scale) | Entire Study Population |
|---|---|
| Week 1 Sleep Disturbance Placebo | 69.32 ± 17.48 |
| Week 1 Sleep Disturbance Pregabalin | 69.29 ± 20.44 |
| Week 7 Sleep Disturbance Placebo | 52.75 ± 24.77 |
| Week 7 Sleep Disturbance Pregabalin | 51.51 ± 26.48 |
| MOS-SS Overall Sleep Index II Baseline Measure (Weeks 1 and 7)(Scores on a Scale) | Entire Study Population |
|---|---|
| Week 1 Sleep Problems Index II Placebo | 62.82 ± 12.96 |
| Week 1 Sleep Problems Index II Pregabalin | 63.21 ± 14.27 |
| Week 7 Sleep Problems Index II Placebo | 47.22 ± 18.38 |
| Week 7 Sleep Problems Index II Pregablin | 48.79 ± 19.89 |
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.